MangoRx Receives Certificate Of Grant In India For Its Respiratory Illness And Preventive Care Technology Patent Application No. 202117034253
Portfolio Pulse from Benzinga Newsdesk
Mangoceuticals, Inc. (NASDAQ:MGRX) has received a Certificate of Grant for its respiratory illness and preventive care technology patent in India. The patent, originally applied for by Intramont Technologies, Inc., is valid for 20 years until March 16, 2040.
August 13, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mangoceuticals, Inc. (NASDAQ:MGRX) has been granted a 20-year patent in India for its respiratory illness and preventive care technology, potentially expanding its market reach and product offerings.
The grant of a 20-year patent in India for Mangoceuticals' respiratory illness and preventive care technology could enhance the company's market presence and product portfolio, likely leading to positive investor sentiment and a potential short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100